Latest Research Findings Offer Potential New Treatments for Acute Myeloid Leukemia
National University of Singapore (NUS)In two separate studies on CEBPA mutations in acute myeloid leukemia (AML) subtypes, researchers led by Professor Daniel Tenen, Director, Cancer Science Institute of Singapore at the National University of Singapore, successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase inhibitors, as potential candidates in the treatment of certain AML.